Mizuho analyst Vijay Rakesh maintains Qualcomm (NASDAQ:QCOM) with a Buy and raises the price target from $168 to $175.
Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data
Johnson & Johnson's results in treating bladder and prostate cancer. Learn about TAR-210's efficacy in high-risk NMIBC patients and TAR-200's promising outcomes for BCG-unresponsive cases.